Report Sections

See All Reports

  • HP:0003003: Colon cancer
  • Pneumonia (361) Abnormality of the cardiovascular system (36) Respiratory tract infection (36) Neoplasm (29) Hypoxemia (28) Diabetes mellitus (25) Depressivity (24) Thromboembolism (23) Acute kidney injury (22) Abnormal lung morphology (21) Anosmia (19) Hypertension (18) Abnormality of coagulation (15) Pulmonary embolism (15) Pulmonary fibrosis (15) Stroke (14) Arthritis (14) Interstitial pneumonitis (14) Myocardial infarction (12) Type II diabetes mellitus (12) Deep venous thrombosis (11) Rheumatoid arthritis (10) Leukemia (10) Respiratory distress (10) Low levels of vitamin D (10) Behavioral abnormality (9) Mental deterioration (9) Chronic pain (9) Congestive heart failure (8) Myocarditis (8) Type I diabetes mellitus (8) Sepsis (8) Infertility (7) Abnormality of the liver (7) Lymphopenia (7) Inflammation of the large intestine (7) Pulmonary obstruction (7) Pulmonary insufficiency (7) Immunodeficiency (6) Systemic lupus erythematosus (6) Chronic pulmonary obstruction (6) Abnormality of the gastrointestinal tract (6) Neoplasm of the lung (6) Encephalopathy (5) Obesity (5) Lymphoma (5) Autoimmunity (5) Breast carcinoma (5) Disseminated intravascular coagulation (5) Fatigue (5) Abnormality of the kidney (4) Coronary artery atherosclerosis (4) Cardiac arrest (4) Headache (4) Colon cancer (4) Arrhythmia (4) Carcinoma (4) Hypercoagulability (4) Autistic behavior (3) Seizure (3) Cardiomyopathy (3) Dysphagia (3) Migraine (3) Pulmonary arterial hypertension (3) Asthma (3) Bronchiectasis (3) Neoplasm of the pancreas (3) Psoriasiform dermatitis (3) Attention deficit hyperactivity disorder (3) Cutaneous melanoma (3) Neoplasm of head and neck (3) Pulmonary edema (3) Insomnia (3) Neoplasm of the large intestine (3) Renal insufficiency (2) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Psychosis (2) Autism (2) Dementia (2) Abnormality of the endocrine system (2) Abnormality of the thyroid gland (2) Jaundice (2) Hepatic fibrosis (2) Premature birth (2) Abnormal heart morphology (2) Abnormality of blood and blood-forming tissues (2) Fever (2) Diarrhea (2) Hypothermia (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Encephalitis (2) Obstructive sleep apnea (2) Male infertility (2) Stillbirth (2) Paroxysmal atrial fibrillation (2) Lymphoid leukemia (2) Myeloproliferative disorder (2) Chronic lymphatic leukemia (2) Renal cell carcinoma (2) Multiple myeloma (2) Abnormal anterior horn cell morphology (2) Amyotrophic lateral sclerosis (2) Sleep apnea (2) Cystoid macular edema (2) Hemeralopia (2) Arteritis (2) Chronic kidney disease (2) Cervix cancer (2) Cholangitis (2) Cholangiocarcinoma (2) Myositis (2) Neuroendocrine neoplasm (2) Neoplasm of the rectum (2) Mania (2) Nephritis (1) Menorrhagia (1) Conductive hearing impairment (1) Cataract (1) Amblyopia (1) Periodontitis (1) Abnormality of the nervous system (1) Oligospermia (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Abnormality of the skin (1) Lymphedema (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Spastic diplegia (1) Hemiparesis (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Tachycardia (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Angina pectoris (1) Pancreatitis (1) Premature rupture of membranes (1) Weight loss (1) Thrombocytopenia (1) Autoimmune thrombocytopenia (1) Gastroesophageal reflux (1) Anorexia (1) Esophageal varix (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Hyperkinetic movements (1) Alzheimer disease (1) Increased intracranial pressure (1) Colitis (1) Biliary cirrhosis (1) Hypotension (1) Vascular dilatation (1) Atherosclerosis (1) Osteoarthritis (1) Tachypnea (1) Hypoventilation (1) Myelodysplasia (1) Neoplasm of the liver (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Reduced factor VIII activity (1) Skeletal muscle atrophy (1) Myalgia (1) Muscular dystrophy (1) Neonatal death (1) Increased body weight (1) Neoplasm of the nervous system (1) Malnutrition (1) Thrombophlebitis (1) Ventricular tachycardia (1) Acute myeloid leukemia (1) Dilatation of the cerebral artery (1) Knee osteoarthritis (1) Monoclonal immunoglobulin M proteinemia (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the stomach (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Renal neoplasm (1) Uterine neoplasm (1) Testicular neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Inflammatory abnormality of the skin (1) Placental abruption (1) Postprandial hyperglycemia (1) Endometrial carcinoma (1) Erythroid hypoplasia (1) Asterixis (1) Glioblastoma multiforme (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Morphea (1) Allergy (1) Non-Hodgkin lymphoma (1) Retinal vein occlusion (1) Heart block (1) Dyspareunia (1) Ductal carcinoma in situ (1) Endometriosis (1) Cardiogenic shock (1) Vulvar neoplasm (1) Addictive behavior (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Neoplasm of the central nervous system (1) Abnormality of movement (1) Ulcerative colitis (1) Crohn's disease (1) Endocarditis (1) Toxemia of pregnancy (1) Neoplasm of the larynx (1) Ovarian neoplasm (1) Vaginal neoplasm (1) Cellulitis (1) Bulimia (1) Atelectasis (1) Esophageal neoplasm (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0003003: Colon cancer

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO

    Correlated Drug Terms (11)

    Name (Synonyms) Correlation
    drug855 Control Test Wiki 0.50
    drug3197 Sublingual Methylene blue Wiki 0.50
    drug1992 Methylene Blue Wiki 0.50
    Name (Synonyms) Correlation
    drug765 Clinical Trial Matching Wiki 0.50
    drug2919 SLEDD with a L-MOD Wiki 0.50
    drug859 Control patients Wiki 0.50
    drug1673 Intracorporeal left hemicolectomy anastomosis Wiki 0.50
    drug3042 Shared Decision Making Wiki 0.50
    drug1231 Extracorporeal left hemicolectomy anastomosis Wiki 0.50
    drug857 Control group Wiki 0.29
    drug610 COVID-19 convalescent plasma Wiki 0.22

    Correlated MeSH Terms (22)

    Name (Synonyms) Correlation
    D003110 Colonic Neoplasms NIH 1.00
    D016889 Endometrial Neoplasms NIH 0.50
    D004938 Esophageal Neoplasms NIH 0.50
    Name (Synonyms) Correlation
    D013274 Stomach Neoplasms NIH 0.50
    D012878 Skin Neoplasms NIH 0.50
    D009423 Nervous System Neoplasms NIH 0.50
    D007680 Kidney Neoplasms NIH 0.50
    D016543 Central Nervous System Neoplasms NIH 0.50
    D005909 Glioblastoma NIH 0.50
    D008113 Liver Neoplasms NIH 0.50
    D007822 Laryngeal Neoplasms NIH 0.50
    D013736 Testicular Neoplasms NIH 0.50
    D002292 Carcinoma, Renal Cell NIH 0.35
    D002583 Uterine Cervical Neoplasms NIH 0.35
    D012004 Rectal Neoplasms NIH 0.35
    D018281 Cholangiocarcinoma NIH 0.35
    D018358 Neuroendocrine Tumors NIH 0.35
    D010190 Pancreatic Neoplasms NIH 0.29
    D006258 Head and Neck Neoplasms NIH 0.29
    D002277 Carcinoma NIH 0.25
    D001943 Breast Neoplasms NIH 0.22
    D008175 Lung Neoplasms NIH 0.20

    Correlated HPO Terms (21)

    Name (Synonyms) Correlation
    HP:0002896 Neoplasm of the liver HPO 0.50
    HP:0008069 Neoplasm of the skin HPO 0.50
    HP:0012114 Endometrial carcinoma HPO 0.50
    Name (Synonyms) Correlation
    HP:0100006 Neoplasm of the central nervous system HPO 0.50
    HP:0010788 Testicular neoplasm HPO 0.50
    HP:0009726 Renal neoplasm HPO 0.50
    HP:0012174 Glioblastoma multiforme HPO 0.50
    HP:0100751 Esophageal neoplasm HPO 0.50
    HP:0004375 Neoplasm of the nervous system HPO 0.50
    HP:0006753 Neoplasm of the stomach HPO 0.50
    HP:0100605 Neoplasm of the larynx HPO 0.50
    HP:0005584 Renal cell carcinoma HPO 0.35
    HP:0100634 Neuroendocrine neoplasm HPO 0.35
    HP:0100743 Neoplasm of the rectum HPO 0.35
    HP:0030153 Cholangiocarcinoma HPO 0.35
    HP:0030079 Cervix cancer HPO 0.35
    HP:0002894 Neoplasm of the pancreas HPO 0.29
    HP:0012288 Neoplasm of head and neck HPO 0.29
    HP:0030731 Carcinoma HPO 0.25
    HP:0003002 Breast carcinoma HPO 0.22
    HP:0100526 Neoplasm of the lung HPO 0.20

    Clinical Trials

    Navigate: Correlations   HPO

    There are 4 clinical trials

    1 SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.

    1. Cancer, Metastatic
    2. Cancer
    3. Cancer of Pancreas
    4. Cancer of Liver
    5. Cancer of Stomach
    6. Cancer Liver
    7. Cancer of Rectum
    8. Cancer of Kidney
    9. Cancer of Esophagus
    10. Cancer of Cervix
    11. Cancer of Colon
    12. Cancer of Larynx
    13. Cancer, Lung
    14. Cancer, Breast
    15. Cancer, Advanced
    16. Cancer Prostate
    17. Cancer of Neck
    18. Cancer of Skin
    19. Neuroendocrine Tumors
    20. Carcinoma
    21. Mismatch Repair Deficiency
    22. BRCA Gene Rearrangement
    23. Non Hodgkin Lymphoma
    24. Leukemia
    25. Non Small Cell Lung Cancer
    26. Cholangiocarcinoma
    27. Glioblastoma
    28. Central Nervous System Tumor
    29. Melanoma
    30. Urothelial Carcinoma
    31. Bladder Cancer
    32. Ovarian Cancer
    33. Endometrial Cancer
    34. Testicular Cancer
    35. Breast Cancer
    36. COVID
    1. Other: Clinical Trial Matching
    MeSH:Carcinoma Glioblastoma Endometrial Neoplasms Neuroendocrine Tumors Cholangiocarcinoma Nervous System Neoplasms Central Nervous System Neoplasms Testicular Neoplasms Pancreatic Neoplasms Breast Neoplasms Lung Neoplasms Esophageal Neoplasms Stomach Neoplasms Liver Neoplasms Colonic Neoplasms Uterine Cervical Neoplasms Rectal Neoplasms Kidney Neoplasms Carcinoma, Renal Cell Skin Neoplasms Head and Neck Neoplasms Laryngeal Neoplasms
    HPO:Breast carcinoma Carcinoma Cervical polyp Cervix cancer Cholangiocarcinoma Clear cell renal cell carcinoma Colon cancer Endometrial carcinoma Esophageal neoplasm Glioblastoma multiforme Neoplasm of head and neck Neoplasm of the breast Neoplasm of the central nervous system Neoplasm of the colon Neoplasm of the larynx Neoplasm of the liver Neoplasm of the lung Neoplasm of the nervous system Neoplasm of the pancreas Neoplasm of the rectum Neoplasm of the skin Neoplasm of the stomach Neuroendocrine neoplasm Papillary renal cell carcinoma Renal cell carcinoma Renal neoplasm Testicular neoplasm

    Primary Outcomes

    Description: CTE Accrual

    Measure: Proportion of patients Eligible for CTE versus Actual CTE

    Time: Through study completion, an average of 1 year

    Secondary Outcomes

    Description: OS

    Measure: Impact of CTE on Overall Survival (OS), estimated by Kaplan-Meier and Cox multivariable survival analysis

    Time: 4 years

    Description: PFS

    Measure: Impact of CTE on Progression-Free Survival (PFS), estimated by Kaplan-Meier and Cox multivariable survival analysis

    Time: 4 years

    Description: To identify barriers to accruals to clinical trials, as measured and reported by a questionnaire

    Measure: Identification of Barriers to CTE

    Time: Through study completion, an average of 1 year

    Description: To Analyze Individual Standard of Care Chemotherapy Utilization (nominal), across treatment lines (numeric); data will be combined and aggregated to report chemotherapy utilization rate (%).

    Measure: Real World Data Analytics

    Time: Through study completion, an average of 1 year

    Description: VTB Use Rate

    Measure: Virtual Tumor Board Utilization

    Time: Through study completion, an average of 1 year

    Description: Time to CTE

    Measure: Time from Intervention to Actual CTE (months)

    Time: Through study completion, an average of 1 year
    2 Patients' Preferences About Rescheduling Colonoscopies Delayed Due to COVID-19: Cross Sectional Study

    The study is a cross-sectional survey study targeting patients aged 45-75 who had their screening or surveillance colonoscopy postponed or delayed due to the COVID pandemic. Study staff will survey a random subsample of patients to assess anxiety, COVID risk tolerance, cancer worry, willingness to screen and barriers to screening colonoscopy, and preference for colonoscopy and alternative colon cancer screening options. Eligible patients will be sent a survey packet in the mail that will include a cover letter, an information sheet describing the study, an incentive, and the survey. The cover letter will include information for participants to opt-out if they desire. Patients will be asked to complete the survey and return it back to study staff. Consent is implied with return of the survey. For the study, staff plan to invite 300 patients and expect to receive 195 completed surveys. Analyses will examine whether COVID-19 has changed patients' interest in colon cancer screening and the strength of patients' preferences for colonoscopy and other approaches to colon cancer screening. It will then examine factors associated with positive and negative views on rescheduling colonoscopies such as anxiety, worry, and risk perceptions.

    1. Colon Cancer
    MeSH:Colonic Neoplasms
    HPO:Colon cancer Neoplasm of the colon

    Primary Outcomes

    Description: Item with 5-point response assessing whether COVID-19 has increased, decreased or not changed interest in colon cancer screening

    Measure: Interest in colon cancer screening

    Time: at start of study--between one week and 2 months after start of study

    Secondary Outcomes

    Description: Item with 5-point response (definitely want to definitely do not want) measuring interest in having a stool test for colon cancer

    Measure: Preference for stool testing

    Time: at start of study--between one week and 2 months after start of study

    Description: Item with 5-point response (definitely want to definitely do not want) measuring interest in postponing colonoscopy for one year

    Measure: Preference for postponing colonoscopy for one year

    Time: at start of study--between one week and 2 months after start of study

    Description: Item with 5 point response (extremely worried to not at all worried) assessing worry about the delay of the colonoscopy on their colon cancer risk

    Measure: Worry about delay

    Time: at start of study--between one week and 2 months after start of study

    Description: Item with 5-point response (very high to very low) assessing patients' perception about risk of getting COVID-19 from having a colonoscopy

    Measure: Risk perception on COVID-19

    Time: at start of study--between one week and 2 months after start of study

    OBJECTIVE: The aim of the study is to demonstrate that the intracorporeal resection and anastomosis in left-sided colon cancer, sigma and upper rectum, is not inferior to extracoprporeal resection and anastomosis, in terms of anastomotic leakage. BACKGROUND: Due to the recent events of a pandemic respiratory disease secondary to infection by SARS-CoV-2 virus or coronavirus 19 (COVID19), surgeons have been forced to adapt our surgical procedures in order to minimize exposure to the virus as much as possible. Based on the recommendations in case of surgery in patients with highly contagious viral diseases, the latest studies suggest minimally invasive accesses to minimize the risk of contagion. One of the proposed measures is the performance of intracorporeal anastomoses. Therefore, given the extensive experience of our center in minimally invasive surgery and studies on the validation of intracorporeal anastomosis techniques in both laparoscopic surgery of the right colon and rectum (TaTME), and the study of advantages that they can provide to the patient, our intention is to apply it to surgery on the left colon, sigma and upper rectum. Our hypothesis is that exteriorization of the colon through an accessory incision increases the risk of tension at the mesocolon level, thus increasing the risk of vascular deficit at the level of the staple area and it may increase the rate of anastomotic leakage. In this sense, studies that validate a standard technique of intracorporeal anastomosis in left colon surgery and that demonstrate its benefit with respect to extracorporeal anastomosis are lacking. We intend to describe a new intracorporeal anastomosis technique (ICA) that is feasible and safe for the patient and that can be applied universally. Once the ICA technique is established, it will allow us to determine its non-inferiority compared to the standard technique performed up to now with extracorporeal anastomosis. METHODS: All consecutive patients with left-sided, sigma and upper rectum adenocarcinoma will be included into a prospective cohort and treated by laparoscopy with totally intracorporeal resection and anastomosis. They will be compared with a retrospective cohort of consecutive patients of identical characteristics treated by laparoscopy with extracorporeal resection and anastomosis, in the immediate chronological period.

    1. Colon Cancer
    1. Procedure: Extracorporeal left hemicolectomy anastomosis
    2. Procedure: Intracorporeal left hemicolectomy anastomosis
    MeSH:Colonic Neoplasms
    HPO:Colon cancer Neoplasm of the colon

    Primary Outcomes

    Description: Percentage of anastomic leak (defined in accordance with Peel et al.).

    Measure: Percentage of anastomotic leak (AL)

    Time: 30 days

    Secondary Outcomes

    Description: Dindo-Clavien Classification

    Measure: Rate of global morbidity

    Time: 30 days

    Description: SSI in accordance with the Center for Disease Control (CDC) National

    Measure: Rate of Surgical site infection

    Time: 30 days

    Description: Percentage of re-interventions due to surgical complications

    Measure: Rate of Re-interventions

    Time: 30 days
    4 Engaging Patients in Colon Cancer Screening Decisions During COVID-19

    The goal of the study is to examine whether a shared decision making intervention improves decision making about colon cancer screening for patients who had their colonoscopy delayed or postponed due to the COVID pandemic. Eligible patients (n=800) will be randomly assigned to either the intervention or control arm. A subset will be surveyed about 6 weeks post intervention to measure shared decision making, their intention to follow through with screening, and their decisional conflict. Study staff will conduct medical chart review to track receipt of colon cancer screening within 6 months. The statistician will test whether patients in the intervention arm report more shared decision making, less decisional conflict, higher intention to follow through on screening and have higher screening rates compared to those in the control arm.

    1. Colon Cancer
    1. Behavioral: Shared Decision Making
    MeSH:Colonic Neoplasms
    HPO:Colon cancer Neoplasm of the colon

    Primary Outcomes

    Description: short patient reported scale asks patients about discussion of options, pros and cons of colonoscopy and discussion of patients' preferences. Total scores range from 0-4 with higher scores indicating higher shared decision making.

    Measure: Shared Decision Making (SDM) Process Scale Score

    Time: 6 weeks after intervention

    Secondary Outcomes

    Description: the 4-item version of the decisional conflict scale, total score ranges from 0-4 with greater scores indicating less decisional conflict.

    Measure: Decisional Conflict (SURE scale)

    Time: 6 weeks after intervention

    Description: One item will assess patients' preferred approach to screening (with responses of colonoscopy, stool card test, no screening, not sure).

    Measure: Patient's preferred approach to screening

    Time: 6 weeks after intervention

    Description: One item will assess patients' intention to follow through with their preferred approach on a 5-point scale from not at all likely to extremely likely.

    Measure: Intention to screen

    Time: 6 weeks after intervention

    Description: Percentage of patients who had completed colon cancer screening test

    Measure: Colon cancer screening rate

    Time: 6 months after randomization

    HPO Nodes


    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  


    4,818 reports on interventions/drugs


    706 reports on MeSH terms


    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook